Jump to content



Recommended Posts

PKS Holdings Limited (PKS) is an Australian healthcare technology company.

It provides a proprietary subscription based Clinical Decision Support system called "RippleDown"; CDS is a health information technology system that is designed to provide health professionals with assistance in clinical decision making tasks.


PKS works with health organisations around the world to better capture, manage and leverage their human expertise to improve the performance of their business and deliver better patient outcomes. PKS supports health organisation capture critical information in an accurate, consistent and reliable manner, across multiple data sources, by applying clinical expertise to all data in real-time.

RippleDown has two components that address a number of the key issues faced by healthcare organisations: - RippleDown Auditor: that enables operational efficiencies through a reduction in data entry errors; and

- RippleDown Expert: that allows faster patient throughput, better patient outcomes and mitigates succession risk

listed in June 2019, at 20c. I notice Perennial, through IFL, has 5.4% and Mirrabooka bought in at IPO with 4.5%

Link to comment
Share on other sites

  • Replies 21
  • Created
  • Last Reply

Top Posters In This Topic

  • 3 months later...
.... PKS has signed a new Software License and Support Agreement with ACT Pathology for its Clinical Decision Support Solution



ACT Pathology, a PKS customer since 2005 provides specialist pathology services at the Canberra Hospital, Calvary Public Hospital Bruce, University of Canberra Hospital, National Capital Private Hospital and in the community through collection centres located across Canberra.


The new agreement which commences on 1 October 2019 is for a 17-month period with an option to extend for an additional 12 months. The value of new agreement is estimated to be $700,000, GST inclusive, over the 29-month period

....I try to take an interest when dealing with medical intervention. A marked aversion, pushback to Technology seems to be an all-too-common reality from the health practitioners I encounter.


Don't rock the boat, it's all too hard, General Ignorance predominate. "Heads down, can't change the system, get paid and don't care". Milk the public teat

Link to comment
Share on other sites

  • 6 months later...

PKS will acquire software-as-a-service healthcare business Pavilion Health, in an all scrip deal that values the target at $8.5 million. Pavilion shareholders will be issued 65.2 million new PKS shares as part of the deal, about 35 per cent of the company post acquisition.


Pavilion is a cloud-based software company that provides audit, risk and consulting software services to hospitals and health bodies. Its customers include 550 hospitals in Australia (owned by the likes of listed giant Ramsay Health Care and private player Healthscope). Established in 2007, Pavilion generated $4.37 million in sales in the 2019 financial year and earnings of $1.66 million.


PKS said it would be looking to combine its software products with Pavilion's to create a more compelling value proposition to potential customers and also facilitate cross-selling and upselling.


PKS offers its customers a clinical decision management system, which uses patient data and clinical expertise to deliver patient-specific reports, recommendations and alerts.

Link to comment
Share on other sites

  • 3 months later...

some steady buying of PKS over the last few days, and hitting an all time high of 26.5c today . No news, but I guess results are due soon.


Together with Alcidion ALC and newly floated Jayex JHL in this sector, I wonder of there is consolidation brewing?

Link to comment
Share on other sites

  • 6 months later...

We should see a near term future (only two to three years away) in which health systems start to move from a world of post-discharge data classification to concurrent computer-assisted coding. This will empower real time data analysis and clinical decision support so that clinical and financial outcomes can be optimized.



PKS is well suited to transform the trusted client relationships it has built over the last two decades into long term development partnerships which will support such a fundamental change in the operating model of healthcare.



Automated coding will be one of the most important data innovations in this decade: it will empower rapid improvement in the sustainability of health services and it will be the foundation stone on which genomics can enter the mainstream of clinical medicine – because it will solve the core problem of precision medicine: access to high quality real-time reference data that can support clinical interpretation of genetic variants.



Our growth strategy has three pillars:

+ rapid scale of our core services, together with new product functionality and expansion in Australian and international markets;

+ development of new complementary products and services, including near real time comprehensive benchmarking services that will support health services understand more about their financial and clinical performance;

+ acceleration in research and development to support automated coding services and the deployment of our best-inclass decision support products in clinical practice beyond pathology.

Link to comment
Share on other sites

  • 4 weeks later...

can only wait and see:

PKS has successfully completed its Share Purchase Plan (SPP) which was announced on 23 February 2021, raising $1,000,000. A total of 2,857,143 new fully paid shares are expected to be issued.


The SPP was strongly supported with 159 shareholders participating. PKS has exercised its discretion to scale back applications.

So, essentially with $30K possible for each SPP investor, anything more than 33 participants and the $1M will be reached.


Meanwhile: firm commitments to raise $12 million through strongly supported placement.

Non-Executive Directors Andrew Gray and Stephen Borness received an allocation in the Placement. New Shares allocated to these parties, totalling 6,342,857 will only be issued subject to receiving shareholder approval at an Extraordinary General Meeting. Assuming approval, individual holdings will be as follows:

• Andrew Gray, via his nominee will increase by $1.75m. This increase will add 5m shares for a total holding of 6.25m shares (approximately 2.9% of total issued shares of the Company)

• Stephen Borness, via his nominee will Increase by $470,000. This increase will add 1,342,857 shares for a total holding of approximately 11.3m shares, and becoming a substantial holder


Indirectly, Investment funds associated with Chairman Mike Hill and Non-Executive Director Brad Lancken also participated in the placement as follows:

• Mike Hill: The Bombora Special Investment Growth Fund increased its stake by approximately $1.75m – Substantial Notice has been issued to the ASX today; and

• Brad Lancken: The Inspire Australian Equities Fund by approximately $200,000.


Help yourselves!! Snouts in the trough.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...